Post Reply
201-220 of 409
nowadays, with medical group/chains. their charges above SG50. They just tender very high price for the clinic space and end up pushing up all prices. Rental cost is the no 1 issue.
2year ago, my family doctor in still charges average of only SGD25 with medication(normal cough and cold medications). But recently, he retired already.
2year ago, my family doctor in still charges average of only SGD25 with medication(normal cough and cold medications). But recently, he retired already.
RichardTeo ( Date: 10-Mar-2022 16:45) Posted:
|
Maybe you' re right, different people different needs.
For me, I just want to see the doctor fast and fxxx off asap after getting the medication. I don' t need if got aircon, nurses pretty, nice decor or not as I am not ging to hang round a clinic. I rather relax somewhere to have coffee or have a beer.
For me, I just want to see the doctor fast and fxxx off asap after getting the medication. I don' t need if got aircon, nurses pretty, nice decor or not as I am not ging to hang round a clinic. I rather relax somewhere to have coffee or have a beer.
Private you are paying for lesser waiting time, more comfortable consultation rooms and lower doctor and nurse to paitent ratios and maybe more exotic medicine. Cater for different markets. Esp now with the pandemic, immune compromise might not want to squeeze in a crowded polyclinic for hours.
I must agree, nowadays doctors charges a lot. Simple cough and cold, charges about SGD40 to SGD50 if you go to those run by Private Chain. But please dont let NTUC comes in. Nowsadays, NTUC is no longer Fair Price. I still prefer Polyclinics..
Wow, even UOB thinks it is a potential takeover target now as it is undervalued.
STOCK IMPACT &bull Potential acquisition target. In Mar 22, Singapore O& G, a listed obstetrics and gynaecology (O& G) company on SGX, received a voluntary unconditional takeover offer from a vehicle wholly-owned by Dymon Asia Private Equity (SE Asia) ll. Singapore O& G provides healthcare services in Singapore and Malaysia, specifically in paediatrics, cancerrelated general surgery, dermatology and O& G, similar to SMG. The cash offer of S$0.295 a share (about 16x 2021 PE) implies a 15.7% and 11.3% premium over Singapore O& G&rsquo s last closing price and a six-month volume weighted average price respectively. Armed with a healthy balance sheet and strong operating segments, we view SMG as an attractive potential acquisition target given that SMG is trading at 9.4x 2021 PE and 8.1x 2022F PE respectively, undervalued as compared with similar SGX listed peers average (17.5x 2021 PE and 14.0x 2022F PE respectively). EARNINGS REVISION/RISK &bull Increase our 2022 and 2023 earnings estimates while adding our 2024 estimate, on the back of a full recovery from COVID-19. We now estimate 2022-24 earnings at S$18.2m (S$16.5m), S$19.4m (S$17.2m) and S$20.4m respectively. VALUATION/RECOMMENDATION &bull Maintain BUY with a higher PE-based target price of S$0.53 (S$0.48 previously), pegged to peers&rsquo average of 14.0X 2022F PE. &bull Assuming a potential offer, we think SMG should be valued at a premium or at least on par with peers&rsquo average, given its expansion in high-growth markets, such as Vietnam&rsquo s aesthetics clinics, telemedicine through HiDoc, as well as solid organic growth initiatives from the addition of medical specialists. &bull The stock is currently trading at an attractive 8.1x 2022F PE. SHARE PRICE CATALYST &bull Recovery in foreign patient load. &bull Earnings-accretive M& As. &bull Stronger traction in high-growth markets, such as Vietnam.
STOCK IMPACT &bull Potential acquisition target. In Mar 22, Singapore O& G, a listed obstetrics and gynaecology (O& G) company on SGX, received a voluntary unconditional takeover offer from a vehicle wholly-owned by Dymon Asia Private Equity (SE Asia) ll. Singapore O& G provides healthcare services in Singapore and Malaysia, specifically in paediatrics, cancerrelated general surgery, dermatology and O& G, similar to SMG. The cash offer of S$0.295 a share (about 16x 2021 PE) implies a 15.7% and 11.3% premium over Singapore O& G&rsquo s last closing price and a six-month volume weighted average price respectively. Armed with a healthy balance sheet and strong operating segments, we view SMG as an attractive potential acquisition target given that SMG is trading at 9.4x 2021 PE and 8.1x 2022F PE respectively, undervalued as compared with similar SGX listed peers average (17.5x 2021 PE and 14.0x 2022F PE respectively). EARNINGS REVISION/RISK &bull Increase our 2022 and 2023 earnings estimates while adding our 2024 estimate, on the back of a full recovery from COVID-19. We now estimate 2022-24 earnings at S$18.2m (S$16.5m), S$19.4m (S$17.2m) and S$20.4m respectively. VALUATION/RECOMMENDATION &bull Maintain BUY with a higher PE-based target price of S$0.53 (S$0.48 previously), pegged to peers&rsquo average of 14.0X 2022F PE. &bull Assuming a potential offer, we think SMG should be valued at a premium or at least on par with peers&rsquo average, given its expansion in high-growth markets, such as Vietnam&rsquo s aesthetics clinics, telemedicine through HiDoc, as well as solid organic growth initiatives from the addition of medical specialists. &bull The stock is currently trading at an attractive 8.1x 2022F PE. SHARE PRICE CATALYST &bull Recovery in foreign patient load. &bull Earnings-accretive M& As. &bull Stronger traction in high-growth markets, such as Vietnam.
SMG announced a record-high PATMI of S$15.6m (+78.8% yoy), beating expectations.
Recovery in demand for the diagnostic and aesthetics segment drove earnings past
pre-pandemic levels. The reopening of international borders will also help the foreign
patient load to recover, which historically contributed 15-20% of annual revenue.
The group continues to make inroads in overseas growth and is focused on key vertical
acquisitions. Maintain BUY with a higher PE-based target price of S$0.53.
UOBKayHian - 10 March 2022
Recovery in demand for the diagnostic and aesthetics segment drove earnings past
pre-pandemic levels. The reopening of international borders will also help the foreign
patient load to recover, which historically contributed 15-20% of annual revenue.
The group continues to make inroads in overseas growth and is focused on key vertical
acquisitions. Maintain BUY with a higher PE-based target price of S$0.53.
UOBKayHian - 10 March 2022
Pretty sure MOH would have asked for industry feedback before announcing these measures. So, how will these measures benefit private medical practise? Is it the fixed provision of subsidy per patient under care for health clusters as opposed to per visits? So now public hospitals and polyclinics will be much more selective in pushing medical services for their clients, leaving a much bigger pie for private clinics to sell theirs?
Invest1 ( Date: 10-Mar-2022 11:28) Posted:
|
Even Singapore O& G is privatised this week. SingMedical surely a more value buy...now at 31 cents is really undervalued. I still hopeful for 2nd en-bloc sales.
I think it has to do with yesterday announcement by MOH on launching " a national enrolment programme, inviting Singapore residents to register with a family doctor of their choice from 2023" .
SingMedical group may benefit from this program. At current price of 31.5c, dividend yield is abt 3% (inclusive of the special dividend). Dyodd.
SingMedical group may benefit from this program. At current price of 31.5c, dividend yield is abt 3% (inclusive of the special dividend). Dyodd.
Havefun2022 ( Date: 10-Mar-2022 10:46) Posted:
|
Why volume so high today? Enbloc news😀 ?
3% not so bad.. better than nothing..
Invest1 ( Date: 23-Feb-2022 11:32) Posted:
|
Bad results go down, good and impressive results also down, die die must go down, no meaning at all. 😂 😂
Not Stingy...but agree with you that should round up to 1 cent. Thou prefer 10cents. Easier to count.
desmondxyz ( Date: 23-Feb-2022 09:57) Posted:
|
Singapore Medical Group net profit up 78.8% to S$15.6m in FY21
DESPITE disruptions to operations and diminishing medical tourism amid the pandemic, Catalist-listed Singapore Medical Group (SMG) on Tuesday (Feb 22) posted a 78.8 per cent rise in net profit to S$15.6 million for the full year ended Dec 31, 2021.
This was largely due to the increase in revenue and a S$1.5 million one-off gain from the remeasurement of previously held equity its joint venture, SMG International (Vietnam).
Revenue rose 15.5 per cent to S$100.8 million for the full year from S$87.3 million the year before. This was attributed to the rising demand across the group' s health and diagnostic and aesthetics segments as well as organic growth at its existing clinics.
Executive director and chief executive Beng Teck Liang said that while the pandemic and absence of medical tourism had weighed on operations, the company was able to tap structural shifts in demand within key specialist verticals such as aesthetics.
This was thanks to the group' s diversified nature in operations as well as the resilient domestic demand for their specialist healthcare services, he said.
Earnings per share for the full year stood at 3.23 Singapore cents, compared with 1.81 cents the previous year.
Net asset value per share came in at 34.53 Singapore cents as at end-2021, versus 31.93 cents as at Dec 31, 2020.
The board of SMG had declared a final dividend of 0.65 Singapore cent per share and a special dividend of 0.25 cent per share.
SMG will be looking to strengthen its position in the women' s and children' s space through the hiring of new obstetrics and gynaecology specialists and paediatricians, as well as the opening of new clinics.
" Our focus remains on the suburban expansion of our specialist services in key verticals where we see strong demand," said Beng.
SMG' s aesthetics segment has also seen " overwhelming demand" . SMG is thus also looking to capture opportunities for growth and further expand its footprint in the aesthetics market.
In a separate announcement on Tuesday, SMG said that it has appointed Mervyn Lim as chief operating officer of the company. He will be responsible for the day-to-day operations of the group, including general clinic operations, marketing, information technology and human resources. Lim was previously vice-president at digital health solutions company ResMed Asia.
so stingy....0.9 cts, should just round it to 1 cts...
josephyeo ( Date: 23-Feb-2022 09:34) Posted:
|
Board of Directors declares a final dividend of 0.65 cents per share (FY2020: 0.4 cents per share)
and a special dividend of 0.25 cents per share to reward shareholders for their continued support
and a special dividend of 0.25 cents per share to reward shareholders for their continued support
SMG reports an all-time high annual revenue of S$100.8 million while net profit surges
78.8% yoy to a record S$15.6 million for FY2021
78.8% yoy to a record S$15.6 million for FY2021
Wow. Very good results and 2.8% dividends. Now can enbloc at higher price liao.
Possible. Can see price maintaining well.
$0.320 hidden buyers today. Against a much bigger sell Q $0.325.
Break out should be quite soon.
Hope so.
$0.320 hidden buyers today. Against a much bigger sell Q $0.325.
Break out should be quite soon.
Hope so.
Invest1 ( Date: 18-Feb-2022 22:24) Posted:
|
Maybe 2nd time enbloc? Hahaha.
AnthonyWoodPeck ( Date: 18-Feb-2022 15:52) Posted:
|